A startup spun out of Jennifer Doudna’s lab has closed an $82 million financing to develop in vivo CAR‑T medicines that aim to reprogram patients’ immune cells inside the body with a single infusion. The funding, disclosed by STAT and company releases, backs preclinical and IND‑enabling work toward single‑administration cell therapies. In vivo CAR‑T seeks to replace ex vivo manufacturing by delivering gene‑editing or gene‑writing payloads systemically or locally to patients’ cells; it is a high‑risk, high‑reward approach with major delivery and safety hurdles. The new capital positions Azalea to advance delivery platforms and early translational studies that, if successful, could dramatically lower costs and expand access to engineered cell therapies.